Recently published Glioblastoma Multiforme Market Insights report includes a comprehensive understanding of current treatment practices, glioblastoma multiforme emerging drugs, market share of ...
A new research perspective was published in Volume 13 of Oncoscience on September 17, 2026, titled "Emerging pharmacological agents for glioblastoma multiforme: An update on active clinical trials ...
Dublin, April 02, 2026 (GLOBE NEWSWIRE)-- The "Glioblastoma Multiforme (GBM) Treatment Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers comprehensive insight ...
BEIJING & BURLINGTON, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and ...
Preliminary clinical data for glioblastoma multiforme patients enrolled in a Phase 1 clinical trial demonstrated that 92 percent of evaluable patients treated with INB-200 exceeded a median ...
Glioblastoma multiforme (GBM) remains the most aggressive primary brain tumour in adults, characterised by rapid proliferation, diffuse infiltration and resistance to conventional therapies. Current ...
Glioblastoma multiforme, the most common and aggressive malignant brain tumor in adults, has long defied the best efforts of neurosurgery, radiation oncology, and chemotherapy. Even with maximal ...
Glioblastoma multiforme (GBM) stands as a formidable adversary in oncology, characterized by its molecular complexity and relentless progression. Despite advancements, the high degree of tumor ...
Glioblastoma multiforme is an aggressive brain tumor that mainly affects adults. Approximately 30,000 people in the U.S. are diagnosed with GBM every year and patients have a 5-year survival rate of 7 ...
(A) Homogenous time-resolved fluorescence (HTRF) assay screening schematic. (B) HTRF assay screening compounds. (C) HTRF assay showed that the effect of FX1, BI-3802, and YK01 blocked the interaction ...
Preliminary clinical data for glioblastoma multiforme patients enrolled in a Phase 1 clinical trial at the University of Alabama at Birmingham demonstrated that 92% of evaluable patients treated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results